Letter to Editor

Cancer Screenings in Primary Care in Türkiye

Volume: 8 Number: 1 April 29, 2024
TR EN

Cancer Screenings in Primary Care in Türkiye

Abstract

The aim of all health screenings, especially cancer screenings, is to increase the survival rate through early diagnosis and treatment. When determining the screening program, many variables are taken into consideration, and actions are taken to improve public health. Health screenings are given immense importance when countries formulate and develop their health policies. If they are appropriate for the health system, health screenings are extremely valuable if they can improve the health of even one person as well as improve public health. As in many countries around the world, cancer screenings are carried out at all health service levels in Turkey, but they are commonly performed for three different types of cancer in primary health care services.

Keywords

References

  1. 1. World Health Organization (WHO). (2021). Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed 11 June, 2023.
  2. 2. Turkish Ministry of Health. (2018). Cancer Statistics in Turkey 2018. Retrieved from https://kanser.gov.tr/Dosya/ca2018.pdf. Accessed 11 June, 2023.
  3. 3. Türkiye Halk Sağlığı Kurumu (TÜRKHAS). (2022). Türkiye Kanser İstatistikleri 2021. https://kanser.gov.tr/Dosya/turkkanseristatistikleri-2021.pdf. Accessed 11 June, 2023.
  4. 4. Aile Hekimliği Uygulama Yönetmeliği. Resmî Gazete Tarihi: 25.01.2013 Resmî Gazete Sayısı: 28539. https://www.resmigazete.gov.tr/eskiler/2013/01/20130125-26.htm. Accessed 15 October, 2022.
  5. 5. Ulusal Kanser Tarama Standartları. T.C.Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü Kanser Dairesi Başkanlığı. https://hsgm.saglik.gov.tr/tr/kanser-tarama-standartlari/listesi.html. Accessed 15 October, 2022.
  6. 6. Kozan R, Tokgöz VY. Türkiye’de Meme Kanseri Farkındalığı ve Tarama Programı. Acıbadem Üniv. Sağlık Bilim. Derg. 2016;7(4);185-188.
  7. 7. Kayhan A, Arıbal E. Meme kanseri taraması: Neden yapıyoruz? Ne zaman? Değerlendirmede yaşanan sorunlar. Trd Sem. 2014;2(2):230-240.
  8. 8. Göksalan H, Uyar EE. Pap smear ile servikal kanser taraması. Türk Aile Hek Derg. 2004;8(3):105-110.

Details

Primary Language

English

Subjects

Clinical Sciences

Journal Section

Letter to Editor

Early Pub Date

April 5, 2024

Publication Date

April 29, 2024

Submission Date

March 8, 2023

Acceptance Date

July 5, 2023

Published in Issue

Year 2024 Volume: 8 Number: 1

APA
Fidancı, İ. (2024). Cancer Screenings in Primary Care in Türkiye. Ahi Evran Medical Journal, 8(1), 1-3. https://doi.org/10.46332/aemj.1262057
AMA
1.Fidancı İ. Cancer Screenings in Primary Care in Türkiye. Ahi Evran Med J. 2024;8(1):1-3. doi:10.46332/aemj.1262057
Chicago
Fidancı, İzzet. 2024. “Cancer Screenings in Primary Care in Türkiye”. Ahi Evran Medical Journal 8 (1): 1-3. https://doi.org/10.46332/aemj.1262057.
EndNote
Fidancı İ (April 1, 2024) Cancer Screenings in Primary Care in Türkiye. Ahi Evran Medical Journal 8 1 1–3.
IEEE
[1]İ. Fidancı, “Cancer Screenings in Primary Care in Türkiye”, Ahi Evran Med J, vol. 8, no. 1, pp. 1–3, Apr. 2024, doi: 10.46332/aemj.1262057.
ISNAD
Fidancı, İzzet. “Cancer Screenings in Primary Care in Türkiye”. Ahi Evran Medical Journal 8/1 (April 1, 2024): 1-3. https://doi.org/10.46332/aemj.1262057.
JAMA
1.Fidancı İ. Cancer Screenings in Primary Care in Türkiye. Ahi Evran Med J. 2024;8:1–3.
MLA
Fidancı, İzzet. “Cancer Screenings in Primary Care in Türkiye”. Ahi Evran Medical Journal, vol. 8, no. 1, Apr. 2024, pp. 1-3, doi:10.46332/aemj.1262057.
Vancouver
1.İzzet Fidancı. Cancer Screenings in Primary Care in Türkiye. Ahi Evran Med J. 2024 Apr. 1;8(1):1-3. doi:10.46332/aemj.1262057

Cited By

Ahi Evran Medical Journal  is indexed in ULAKBIM TR Index, Turkish Medline, DOAJ, Index Copernicus, EBSCO and Turkey Citation Index. Ahi Evran Medical Journal is periodical scientific publication. Can not be cited without reference. Responsibility of the articles belong to the authors.

    Creative Commons Lisansı

This journal is licensed under the Creative Commons Atıf-GayriTicari 4.0 Uluslararası Lisansı.